Novartis says Phase III RemIND trial shows Rhapsido hits endpoints in chronic inducible urticaria
PUBT · 10h ago
Share
Listen to the news
- Novartis presented Phase III RemIND data at the EAACI congress, showing Rhapsido improved symptom control across common chronic inducible urticaria subtypes.
- Results supported sustained relief in patients not adequately controlled on standard antihistamines, with responses emerging early in parts of the study.
- Safety profile remained favorable, with no liver safety signal reported in the trial readout.
- Regulatory review is underway in the US for the symptomatic dermographism subtype, positioning Rhapsido as a potential first targeted option in CIndU.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606120536OMX_____CNEWS_EN_GNW1001187340_en) on June 12, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved